Catalyst Pharmaceuticals, Inc.
Florida
United States
343 articles about Catalyst Pharmaceuticals, Inc.
-
Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development
8/20/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Stanley Iyadurai, M.D., Ph.D. as Vice President of Clinical Development.
-
Catalyst Pharmaceuticals Announces Second Quarter 2018 Financial Results and Provides Corporate Update
8/7/2018
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a corporate update.
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse
2/12/2018
Resubmission of NDA for Firdapse on schedule for end of the first quarter.
-
Catalyst Pharma to Present at Two Upcoming Investor Conferences
2/8/2018
The presentation materials for the BIO CEO & Investor conference will be posted at www.catalystpharma.com in the Investor section under Events and Presentations.
-
These companies are important to follow as they have exponential growth potential and are working on new and innovative drugs.
-
Catalyst Pharmaceuticals Announces Closing of Previously Announced Public Offering - Dec. 1, 2017
12/1/2017
Piper Jaffray & Co. acted as the lead bookrunner. SunTrust Robinson Humphrey, Inc. also acted as a bookrunner.
-
Catalyst Pharma Announces Proposed Public Offering of Common Stock
11/28/2017
All of the shares in the offering are being sold by Catalyst.
-
This trial had two prospectively defined co-primary endpoints.
-
Catalyst Pharmaceuticals Announces Phase II Study of Firdapse in Ambulatory Patients With Spinal Muscular Atrophy (SMA)
11/21/2017
The study will be conducted by a team of researchers led by Lorenzo Maggi, MD, and Giovanni Baranello, MD, of the Fondazione Istituto Neurologico Carlo Besta in Milan, Italy, a major referral center for SMA patients.
-
Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update
11/9/2017
For the quarter ended September 30, 2017, Catalyst reported a GAAP net loss of $4,177,649, or $0.05 per basic and diluted share, compared to a GAAP net loss of $3,953,981.
-
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017
11/1/2017
Catalyst management will host a conference call at 8:30 a.m. EST to discuss the financial results and to provide a corporate update.
-
Catalyst Pharmaceuticals Completes Enrollment in Second Phase III Trial of Firdapse in Patients With Lambert-Eaton Myasthenic Syndrome
10/31/2017
Top-Line results are expected in early December.
-
Catalyst Pharma Provides Update On The Status Of Its Firdapse Development Activities
8/30/2017
-
Catalyst Pharma Announces Second Quarter 2017 Financial Results And Provides Corporate Update
8/10/2017
-
Catalyst Pharma To Hold Second Quarter Financial Results Conference Call And Webcast On Thursday, August 10th, 2017
8/1/2017
-
Catalyst Pharma Joins Russell 3000 Index
6/26/2017
-
Catalyst Pharma To Present At The Jefferies 2017 Healthcare Conference
6/1/2017
-
Catalyst Pharma To Present At The Antiepileptic Drug And Device Trials XIV Symposium
5/17/2017
-
Catalyst Pharma Receives 2017 Beacon Council Award For Contributions In Life Sciences & Healthcare
5/15/2017